12 / 24
PFS by investigator assessment
0
6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60
0
10
20
30
40
50
60
70
80
90
100
3
Investigator-assessed
progression-free survival (%)
Months since randomization
Olaparib
Placebo
Olaparib
(N=260)
Placebo
(N=131)
Events (%) [50.6% maturity]
102 (39.2)
96 (73.3)
Median PFS, months
NR
13.8
HR 0.30
95% CI 0.23, 0.41;
P
<0.0001
NR, not reached
260 229 221 212 201 194 184 172 149 138 133 111 88 45 36 4 3 0 0 0
240
Olaparib
131
103 82 65 56 53 47 41 39 38 31 28 22 6 5 1 0 0 0 0
118
No. at risk
Placebo
60%
27%